Background and Purpose-Brain iron overload is a key factor causing brain injury after intracerebral hemorrhage (ICH).
It is important to develop reliable and noninvasive methods to quantify brain iron levels for experimental and clinical studies. Magnetic resonance imaging (MRI) can detect parenchymal hematomas and iron with high sensitivity. Tissue iron shortens T2* relaxation times measured by MRI. T2* gradient-echo imaging has been used to assess hematoma size early after ICH and brain iron accumulation at later phases. 6, 7 The reciprocal of T2*, known as (relaxivity) R2*, is directly proportional to iron concentration with studies describing a near-linear rise in R2* with iron concentration. 8, 9 Mapping of the relaxation rate R2* represents an indirect measure of iron. 8, 10, 11 Minocycline-a second-generation tetracycline-based molecule-is a potent inhibitor of microglia activation that can penetrate the brain-blood barrier easily. We and others have demonstrated that minocycline is able to chelate iron in vitro and in vivo. 12, 13 This study investigated the time course of perihematomal iron in an ICH model in aged rats using MRI R2* mapping. It then examined whether minocycline can reduce ICH-induced iron overload and brain injury.
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(online-only Data Supplement). A total of 67 18-month-old male Fischer 344 rats (National Institutes of Health, Bethesda, MD) were used in this study. The ICH model was performed as described previously. Rats were anesthetized with pentobarbital (45 mg/kg IP). Core body temperature was maintained at 37.5±0.5°C by a feedback-controlled heating pad. The right femoral artery was inserted with a polyethylene catheter to obtain blood for injection and to monitor arterial blood pressure, blood gases, and glucose concentrations. Rats were positioned in a stereotactic frame (Kopf Instruments, Tujunga, CA), and a cranial burr hole (1.0 mm) was drilled on the right coronal suture 3.5 mm lateral to midline. A 26-gage needle was inserted stereotactically into the right basal ganglia (coordinates: 0.2 mm anterior, 5.5 mm ventral, and 3.5 mm lateral to bregma). Autologous arterial blood or saline of 100-μL was injected for 10 minutes with a micro infusion pump.
Experimental Groups
Rats had an intracaudate injection of 100-μL autologous arterial blood (ICH) or saline (control). The animals were randomized using selection of odd or even numbers. In the first part of the study, rats were euthanized at day 7 or 28 after ICH or saline injection (n=7-8 in each group). Serial MRI scan was performed at different time points (days 1-28). In the second part of the study, ICH rats were treated with minocycline (20 mg/kg IP at 2 and 12 hours after ICH followed by 10 mg/kg BID ≤7 days) or vehicle (saline; n=8 in each group). The minocycline dose was determined in our preliminary study. We found that high doses of minocycline (45 mg/kg IP at 2 and 12 hours after ICH followed by 22.5 mg/kg BID ≤7 days) resulted in high mortality rate (≈50%) in aged rats. MRI scan was performed, and the rats were euthanized at day 7 or 28. All rats had behavioral tests. Harvested brains were used for immunohistochemistry and Western blot analysis.
Magnetic Resonance Imaging
Rats were anesthetized with ≈1.5%-2% isoflurane throughout MRI examination. T2-weighted, T2* gradient-echo, and T2* array imaging were performed in a 7.0-T Varian MR scanner (Varian, Palo Alto, CA). T2-weighted and T2* gradient-echo imaging (repetition time/ echo time, 4000/60 and 200/5 ms for T2 and T2* imaging, respectively) were performed as described previously. 14 The T2 and T2* images were taken to measure ventricular and T2* lesion volumes. The bilateral ventricles and T2* lesion were outlined for area measurement in National Institutes of Health ImageJ. Total volumes were obtained by combining the areas and multiplying by the thickness (0.5 Figure 1A ) and 3 corresponding areas in the contralateral hemisphere ( Figure 1A) were measured. The perihematomal regions were determined on T2* images for each animal. A series of standard iron concentration (14, 28, 56, 112 , and 224 μg/mL; ferric chloride solution, 157740-5G; Sigma-Aldrich) solutions in test tubes were also scanned under T2* array. There was a near-linear correlation between the R2* value on MRI images and the iron concentration of the standard solutions ( Figure 1A ). The brain iron content was calculated from that correlation.
Immunohistochemistry
Immunohistochemistry staining was performed as described previously.
14 Briefly, rats were anesthetized with pentobarbital (100 mg/ kg IP) and perfused with 4% paraformaldehyde in 0.1 mol/L phosphate-buffered saline (pH 7.4). Brains were harvested and kept in 4% paraformaldehyde for 24 hours, and then immersed in 30% sucrose for 3 to 4 days at 4°C. After embedding in a mixture of 30% sucrose and optimal cutting temperature compound (Sakura Finetek, Inc, Torrance, CA) at a ratio of 1:2, brains were sectioned at 18 μm on a cryostat. Immunohistochemistry studies were performed with avidinbiotin complex techniques. Primary antibodies were polyclonal rabbit anti-HO-1 (heme oxygenase-1; ADI-SPA-895-F, 1:400 dilution; Enzo), polyclonal rabbit anti-ferritin IgG (1:500 dilution; AbD), and polyclonal rabbit anti-DARPP-32 (dopamine-and cAMP-regulated phosphoprotein Mr 32 kDa Ig G 1:500 dilution; Cell Signaling).
Enhanced Perls Reaction
Brain sections were incubated in Perls solution (1:1, 5% potassium ferrocyanide and 5% HCl) for 45 minutes, washed in distilled water, and incubated again in 0.5% diamine benzidine tetrahydrochloride with nickel for 60 minutes.
Western Blots
Western blot analysis was performed as described previously.
14 Primary antibodies were polyclonal rabbit anti-HO-1 (ADI-SPA-895-F, 1:1000 dilution; Enzo), polyclonal goat anti-FTL (ferritin light chain) IgG (1:2000 dilution; Abnova, Walnut, CA), polyclonal rabbit anti-FTH (ferritin heavy chain) IgG (1:2000 dilution; Cell Signaling, Beverly, MA), polyclonal rabbit anti-DARPP-32 (1:10 000 dilution; Cell Signaling, Beverly, MA), monoclonal rabbit anti-β-actin (1:10 000 dilution; Cell Signaling, Beverly, MA), and monoclonal mouse anti-GAPDH (10R-G109A, 1:10 000 dilution; Fitzgerald).
Behavioral Tests
Functional outcomes were assessed using forelimb placing and corner turn tests. 15 The 2 behavioral tests were performed by an investigator (Y.H.) who was blinded to the treatment.
Statistical Analysis
All the data are expressed as means±SD. Data were analyzed by Student t tests or 1-and 2-way ANOVA with a Scheffe multiple comparisons test. Differences were considered significant at P<0.05. A power analysis indicated that n=8 in the vehicle and minocycline groups would have >80% power to detect a 25% change in T2* lesion volume. The same group sizes were estimated to have 95% power to detect a 15% change in tissue iron.
Results
Mortality rate after ICH was low in this aged rat study. A total of 4 rats died during the experiments, including 2 in the first set of experiments (2 ICH rats) and 2 in the second set (1 vehicletreated and 1 minocycline-treated rat). Significant side effects resulting from minocycline treatment, such as diarrhea, were not observed during our experiments.
ICH Induces Iron Deposition in Perihematomal Brain Tissue
MRI R2* mapping was used to determine brain iron content in perihematomal area. Iron levels in the hematoma were too high for R2* mapping. The near-linear correlation between R2* value and iron content was excellent from 14 to 224 μg/ mL in test tubes (correlation coefficient, 0.9996; Figure 1A ). Using the contralateral hemisphere as a control, we found that the brain iron content around the hematoma increased gradually over the time after ICH with a peak at day 14 and stayed high at 1 month ( Figure 1B ). Compared with controls receiving an intracerebral injection of saline, brain iron content was significantly increased in the side ipsilateral to the hematoma but not the contralateral hemisphere at day 7 after ICH ( Figure 2 ).
Minocycline Reduces Brain Iron Overload After ICH in Aged Rats
Whether minocycline can attenuate brain iron overload after ICH in aged rats was examined. Minocycline reduced brain iron levels in perihematomal area at both days 7 (73.4±8.4 versus 88.0±9.7 μg/mL in the vehicle-treated ICH animals; P<0.01) and 28 (76.4±9.4 versus 92.9±10.4 μg/mL with vehicle treatment; P<0.01). By enhanced Perls staining, an iron-positive area was also found in the perihematomal zone, corresponding to the images from MRI R2* mapping 
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( Figure 3A ). Our previous study demonstrated that MRI T2* changes in the brain correlated closely with the hematoma in the acute phase and brain iron overload in the chronic phase after ICH. 6 Thus, the volume of T2* was determined. The T2* lesion volume was decreased in the minocycline-treated group both at days 7 (33.6±7.8 versus 39.9±10.0 mm 3 in the vehicletreated group; P<0.05; Figure 3B) Figure 3B ). HO-1 is a key enzyme for heme degradation. HO-1 was upregulated in the perihematomal zone after ICH in aged rats, and minocycline attenuated the increased HO-1 expression compared with vehicle treatment at day 7 (P<0.05; Figure 4A ). Ferritin-an iron storage protein-was associated with brain iron deposition after ICH. Ferritin-positive cells were less in minocycline-treated rats at day 7 ( Figure 4B ). Western blot analysis also showed that both FTL and FTH levels were lower in the minocycline-treated group compared with the vehicle-treated group at day 7 (P<0.05; Figure 4B ).
Minocycline Attenuates ICH-Induced Neuronal Death, Neurological Deficits, and Brain Atrophy in Aged Rats
DARPP-32-a specific marker of neurons in the basal ganglia-was used as a simple and reliable maker for neuronal injury after experimental ICH. Using Western blot analysis and immunochemistry staining, DARPP-32 levels in the ipsilateral basal ganglia were decreased significantly after ICH compared with saline group (P<0.05; Figure 5 ) at day 7. Minocycline treatment reduced this ICH-induced caudate neuronal death (P<0.05; Figure 5 ).
To assess behavioral deficits, forelimb placing and corner turn test were used. Compared with controls receiving an intracerebral saline injection, ICH caused significant neurological deficits at day 1 in both minocycline-and vehicle-treated groups. At days 7 and 28, however, the minocycline-treated ICH group had less neurological deficits than vehicle-treated rats (P<0.05; Figure 6 ).
To estimate brain atrophy, we measured ventricular enlargement at day 28 after ICH. T2-weighted MRI showed marked enlargement of the ipsilateral ventricle after ICH. That enlargement was significantly less with minocycline treatment (189±97%) compared with vehicle treatment (314±92%, n=8; P<0.05).
Discussion
The major findings of this study are as follows: (1) MRI R2* mapping was a reliable and noninvasive method of quantitative measure for brain iron overload after ICH, (2) minocycline treatment reduced brain iron overload after ICH in aged rats, and (3) minocycline attenuated ICH-induced brain injury and improved functional outcome in aged rats.
Iron-a hemoglobin degradation product-has a major role in brain damage after ICH. 1 Iron can accumulate in the perihematomal zone after erythrocyte lysis after ICH, 
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contributing to acute brain edema formation and delayed brain atrophy. 2, 3, 16 Both early brain edema and delayed brain tissue loss cause neurological deficits after ICH. Iron content in the perihematomal area could be high for several weeks after ICH. Our previous biochemical study showed that there was a 3-fold increase of brain nonheme iron in the perihematomal zone after ICH in young rats. 4 ICH is, however, mostly a disease of the elderly, and this study using MRI R2* mapping detected the natural time course of brain iron accumulation in perihematomal zone in the aged rat ICH model. It should be noted that the pattern of brain iron overload measured by MRI was similar to that determined by nonheme iron assay. 4 Although there is a large body of evidence for the role of iron in brain damage after parenchymal hemorrhage, there is lack of reliable and noninvasive methods for accurate quantification of the tissue iron content. Following such demands, existing noninvasive modalities, such as MRI, have been utilized to develop iron measurement not only in the brain tissue but also in the liver and heart. [8] [9] [10] Paramagnetic effects of tissue-deposited iron, as a form of signal inhomogeneity, have been exploited to estimate tissue iron content. Our previous study demonstrated that T2*-weighted MRI changes in the brain correlate closely with brain iron overload after ICH. 6 Another study showed the feasibility of brain iron measurement in a normal aging population by quantitative susceptibility mapping. 17 With the further studies in this field, many investigators described the near-linear rise in R2*(1/T2*) and R2 (1/T2) signal with iron content. 8, 9, 18, 19 Mapping of the relaxation rate R2* represents an indirect measure of iron. It has been reported that MRI R2* mapping could accurately estimate hepatic iron content in patients with sickle cell disease. 8 Our group has demonstrated proof of principle for brain iron measurement by using MRI R2* mapping in 2 patients with ICH. 20 The present study was to quantitatively detect perihematomal brain iron content by MRI R2* mapping in the aged rat ICH model. The results suggested a gradual increase of iron accumulation in perihematomal zone in aged rat and a plateau around 2 weeks after ICH. The MRI brain tissue iron quantification may provide a noninvasive way for examining brain iron levels after hemorrhagic stroke in animals and in patients. However, it was not possible to measure iron levels in the hematoma at acute phase (too high) or in the cavity at chronic phase after ICH.
Minocycline has been reported to provide neuroprotection in both hemorrhagic and ischemic animal models. 12, 21, 22 Our previous studies have demonstrated that minocycline acts as an iron chelator and an inhibitor of microglial activation and can reduce ICH-induced brain iron overload and brain injury. 21 Another in vitro study showed that minocycline could attenuate iron neurotoxicity in cortical neuronal cultures. 23 Further research has proven that the iron chelate effect of minocycline, but not the inhibition effect of microglial activation, attenuated iron-induced brain edema and blood-brain barrier disruption. 12 In the current study, we demonstrated that minocycline reduced ICH-induced brain injury in aged rats with decreasing iron deposition in perihematomal zone. We hypothesize that minocycline chelates iron within or close to the hematoma preventing the spread of iron into perihematomal tissue. As an antibiotic, minocycline can be administered orally, and it maintains effective blood drug concentration through intestinal absorption. It is also a highly lipophilic compound that penetrates the blood-brain barrier easily. The results suggested that minocycline may be a promising treatment for patients with ICH.
The mechanisms of minocycline-induced brain protection after ICH are complicated. It is well known that minocycline is an inhibitor of microglia, but it is also an iron chelator. 12 In the current study, we found that minocycline reduces perihematomal HO-1 expression at day 7, and the most of HO-1-positive cells are microglia/macrophages. It is still unclear whether reduced HO-1 expression in minocycline-treated animals results from microglia inhibition, iron chelation, or both. Microglia/macrophage polarization has an important role in hematoma clearance and brain recovery after ICH, 24, 25 and future studies should examine the role of minocycline in microglia/macrophage polarization, clot resolution, and brain recovery. It should be noted that minocycline inhibited M1 polarization in a mouse model of amyotrophic lateral sclerosis. 26 Minocycline also reduces ICH-induced upregulation of ferritin in the perihematomal zone. Most of ferritin-positive cells are glia. Our previous study demonstrated that perihematomal ferritin-positive cells are microglia and astrocytes. 4 Because astrocytes have a role in brain iron overload, 27 it will be interesting to examine the effects of minocycline on astrocyte activation after ICH. The current study focused on brain iron quantification by MRI R2* mapping and the effect of minocycline on ICHinduced brain injury in aged rats. There are several limitations in this study: (1) it is unclear whether MRI R2* mapping measures intracellular or extracellular iron, whether R2* signal may change during changes in iron oxidation or protein binding; (2) the correlation between iron standards and R2* was determined in test tubes; (3) minocycline was only tested in aged male rats. It is important to examine whether minocycline also can reduce ICH-induced brain iron overload and brain injury in aged female animals; (4) only 1 dose of minocycline was tested. Further translational studies should determine optimal dose, optimal durations, and therapeutic window for minocycline.
In conclusion, brain iron accumulation occurs after ICH in aged rats, which can be measured by MRI R2* mapping. Minocycline reduces ICH-induced brain iron overload as assessed by R2* mapping and brain injury in aged rats and could be an effective treatment for patients with ICH. MRI R2* mapping is a method for quantitatively assessing iron overload and iron-focused treatments in cerebral hemorrhage. 
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